Toyonaka, Japan

Kyozo Tsukamoto


Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 29(Granted Patents)


Location History:

  • Toyonaka, JP (1986)
  • Suita, JP (1987)

Company Filing History:


Years Active: 1986-1987

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Kyozo Tsukamoto

Introduction

Kyozo Tsukamoto, an accomplished inventor based in Toyonaka, Japan, has made significant strides in the field of biotechnology. With two patents to his name, he has been instrumental in advancing our understanding and application of peptides and messenger RNA.

Latest Patents

Tsukamoto's recent patents include a groundbreaking invention around a novel peptide and its use. This invention relates to a specific polypeptide formula that enables the detection and purification of human gamma-interferon through the use of monoclonal antibodies derived from the polypeptide. His second notable patent focuses on a method for producing human Interleukin 2-encoding messenger RNA that is free of human cells. This innovative approach utilizes cells capable of synthesizing human Interleukin 2, offering new avenues for protein synthesis in vitro.

Career Highlights

Kyozo Tsukamoto is a notable figure at Takeda Chemical Industries, Inc., where he has contributed to impactful research in the pharmaceutical industry. His work primarily revolves around the development of biopharmaceuticals, showcasing his dedication to innovation and improvement in health care solutions.

Collaborations

Throughout his career, Tsukamoto has worked alongside distinguished colleagues such as Shuji Hinuma and Haruo Onda. Their collaboration has fostered advancements in research and product development, amplifying the impact of their collective expertise within the biotechnology domain.

Conclusion

Kyozo Tsukamoto's innovative patents and collaborative efforts mark him as a significant contributor to the fields of peptide research and messenger RNA applications. His work continues to pave the way for future advancements in biopharmaceuticals, reaffirming his position as a leading inventor in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…